This study intends to further explore the actual efficacy of ustekinumab in the individualized treatment of anal fistula Crohn's disease.
Clinical diagnosis of Perianal Fistulizing Crohn's Disease
Receive ustekinumab therapy
Ustekinumab combined with hormones, immunosuppressants, other biologics or small molecule drugs
Combined with other autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Graves disease, etc.
Combined with serious infectious diseases, such as active tuberculosis, EBV infection, cytomegalovirus infection, etc.
Combined with malignant tumor
patients with perianal fistulizing Crohn's disease
Cohort
Retrospective
Not listed
imaging remission rate of anal fistula
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
